Abstract Number: 62 • 2019 ACR/ARP Annual Meeting
Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway
Background/Purpose: Cell specific and cytokine targeted therapeutics have underperformed in systemic lupus erythematosus (SLE) in spite of numerous targets examined and clinical trials conducted. Mesenchymal…Abstract Number: 1018 • 2019 ACR/ARP Annual Meeting
Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
Background/Purpose: Compared to Caucasian, African-American ethnicity is associated with a higher risk of developing systemic lupus erythematosus, lupus nephritis, high-risk histological features, resistance to treatment,…Abstract Number: 2528 • 2019 ACR/ARP Annual Meeting
Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis
Background/Purpose: Hydroxychloroquine(HCQ) is recommended for all patients with SLE in EULAR recommendation 2019, however, there are not enough data about the effect of additional HCQ…Abstract Number: 65 • 2019 ACR/ARP Annual Meeting
CD6 Modulation Ameliorates Skin and Kidney Disease in a Spontaneous Murine Model of SLE
Background/Purpose: T cells are an important contributor the pathogenesis of SLE and its various end organ manifestations. Thus, they present themselves as potential therapeutic targets;…Abstract Number: 1128 • 2019 ACR/ARP Annual Meeting
Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
Background/Purpose: The quality of physician-patient interaction can have a significant impact on medication adherence. Little is known about this relationship in patients with lupus nephritis…Abstract Number: 2542 • 2019 ACR/ARP Annual Meeting
An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis
Background/Purpose: Achieving clinical remission while reducing toxicity are primary objectives in the treatment of lupus nephritis (LN). Mycophenolate mofetil (MMF) has demonstrated efficacy benefits with…Abstract Number: 66 • 2019 ACR/ARP Annual Meeting
Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
Background/Purpose: CD6 is a co-stimulatory receptor on T cells, that binds to activated leukocyte cell adhesion molecule (ALCAM), a ligand expressed on antigen presentation cells…Abstract Number: 1564 • 2019 ACR/ARP Annual Meeting
Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis
Background/Purpose: Patients with lupus nephritis (LN) have a 9-fold higher risk of cardiovascular disease (CVD), highlighting the urgent need to target CVD prevention. Studies in…Abstract Number: 2556 • 2019 ACR/ARP Annual Meeting
Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN
Background/Purpose: Current therapeutic management of active Class III or IV proliferative LN relies on the use of maintenance therapy following induction. The optimal method for…Abstract Number: 72 • 2019 ACR/ARP Annual Meeting
The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease
Background/Purpose: Lupus nephritis is a complex and heterogeneous disease characterized by infiltrating immune cells in damaged kidney tissue. While mouse models have enabled mechanistic studies…Abstract Number: 1566 • 2019 ACR/ARP Annual Meeting
HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
Background/Purpose: Lupus nephritis is a common feature of SLE and confers a poor prognosis. 20-50% of patients with lupus nephritis ultimately develop chronic kidney disease…Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…Abstract Number: 639 • 2019 ACR/ARP Annual Meeting
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Background/Purpose: African-Americans lupus nephritis is more common than in Caucasians, more severe and more likely to lead to end stage renal disease. We asked whether…Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting
Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates
Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 37
- Next Page »